CD274 and non-small cell lung carcinoma: The results from KEYNOTE-18968 and its predecessor Phase 2 KEYNOTE-021 trial70,71 led to the widespread approval of pembrolizumab in combination with platinum and pemetrexed for the first-line treatment of metastatic non-squamous NSCLC in patients without EGFR or ALK genomic tumour aberrations, regardless of PD-L1 expression.